Vertex And Merck Neck-To-Neck In HCV Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.
You may also be interested in...
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
Protease Inhibitors Could Get Hepatitis C Market Boost From CDC Funding Request
A series of federal public health initiatives are aligning to expand the market for the first two protease inhibitors expected to win approval for hepatitis C treatment.